慢性乙型肝炎患者的乙型肝炎表面抗原会消失吗?——西方观点
Anna S.Lok
摘要(Abstract)：
<正>乙肝表面抗原(HBsAg)发现迄今已有50年历史,随着研究的进展,人们对HBsAg的认识越来越深入。那么,HBsAg会消失吗?HBsAg消失后患者的预后会有何变化?本文将阐述"慢性乙型肝炎(CHB)患者的HBsAg会消失吗"——西方观点,主要包括以下四个方面内容:①HBsAg的自发清除;②抗病毒治疗诱导的HBsAg清除;③HBsAg清除后的预后;④HBsAg清除的可逆性。
关键词(KeyWords)：
基金项目(Foundation):
作者(Author): Anna S.Lok
参考文献(References)：
- [1]Sampliner RE,Hamilton FA,Iseri OA,et al.The liverhistology and frequency of clearance of the hepatitis B surfaceantigen(HBsAg)in chronic carriers[J].Am J Med Sci,1979,277(1):17-22.
- [2]Perrillo R P,Brunt E M.Hepatic histologic and immunohistochemical changes in chronic hepatitis B afterprolonged clearance of hepatitis B e antigen and hepatitis Bsurface antigen[J].Ann Intern Med,1991,115(2):113-115.
- [3]Loriot MA,Marcellin P,Bismuth E,et al.Demonstration ofhepatitis B virus DNA by polymerase chain reaction in theserum and the liver after spontaneous or therapeutically inducedHBeAg to anti-HBe or HBsAg to anti-HBs seroconversionin patients with chronic hepatitis B[J].Hepatology,1992,15(1):32-36.
- [4]Kuhns M,McNamara A,Mason A,et al.Serum and liverhepatitis B virus DNA in chronic hepatitis B after sustained lossof surface antigen[J].Gastroenterology,1992,103(5):1649-1656.
- [5]Simonetti J,Bulkow L,McMahon BJ,et al.Clearance ofhepatitis B surface antigen and risk of hepatocellular carcinomain a cohort chronically infected with hepatitis B virus[J].Hepatology,2010,51(5):1531-1537.
- [6]Fattovich G,Giustina G,Sanchez-Tapias J,et al.Delayedclearance of serum HBsAg in compensated cirrhosis B:relationto interferon alpha therapy and disease prognosis[J].Am JGastroenterol,1998,93(6):896-900.
- [7]Buster E,Flink HJ,Cakaloglu Y,et al.Sustained HBeAgand HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b[J].Gastroenterology,2008,135(2):459-467.
- [8]Heathcote EJ,Marcellin P,Buti M,et al.Three-year efficacyand safety of tenofovir disoproxil fumarate treatment forchronic hepatitis B[J].Gastroenterology,2011,140(1):132-143.
- [9]Gish R,Chang TT,Lai CL,et al.Loss of HBsAg antigenduring treatment with entecavir or lamivudine in nucleoside-na ve HBeAg-positive patients with chronic hepatitis B[J].JViral Hepat,2010,17(1):16-22.